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Abstract
Summary Early PINP changes correlate with 18-month lumbar spine BMD changes and the correlation was greater with
abaloparatide versus teriparatide. The uncoupling index was similar between the two agents.
Introduction We evaluated the relationship between early PINP changes and subsequent changes in spine BMD following
abaloparatide and teriparatide treatments. We also explored the use of an Buncoupling index^ (UI), the balance between bone
formation and bone resorption, which we hypothesised would be similar in response to these treatment groups.
Methods Blood samples were taken for measurement of bone turnover markers (BTMs) s-PINP and s-CTX at baseline, 1, 3, 6,
12, and 18 months from 189 abaloparatide patients and 227 teriparatide patients randomly selected from all participants who
completed the study. BMD was measured by DXA at baseline, 6, 12, and 18 months. Correlations were calculated between log
ratio of BTMs from baseline to 3 months and percent change from baseline in BMD at 18 months. A UI was calculated using log
transformation and subtraction of the standard deviate for s-CTX from the standard deviate for s-PINP for each patient.
Results Early BTM changes were associated with subsequent BMD changes for both treatments. Pearson correlations for the log
ratio of PINP over baseline at 3 months and BMD percent change from baseline at 18 months were larger (P < 0.0001) with
abaloparatide (r = 0.561) than teriparatide (r = 0.198). The mean UI at 1 month was greater for abaloparatide versus teriparatide
(1.743 and 1.493, respectively; P = 0.03) but was similar at 3 months or later time points.
Conclusions Early s-PINP changes correlate with percentage change in lumbar spine BMD 18 months after treatment with both
abaloparatide and teriparatide, though the correlation with abaloparatide was greater. The UI was similar between abaloparatide
and teriparatide suggesting that the balance between formation and resorption markers was similar.
Keywords Abaloparatide . Bone mineral density . Bone turnover markers . Procollagen type I N propeptide . Teriparatide .
Uncoupling index
Introduction
Abaloparatide [1] is a synthetic peptide analogue of the human
parathyroid hormone-related protein used in the treatment of
postmenopausal osteoporosis in women at high risk for frac-
ture. Abaloparatide binds to the parathyroid hormone 1 recep-
tor, similar to teriparatide or PTH 1-34. Recent in vitro studies
indicate that there are at least two stable, high-affinity PTHR1
conformations, R0 and RG. Binding to R0 results in prolonged
signalling responses in cells and prolonged calcemic re-
sponses in animals, whereas selective binding to RG results
in more transient responses. Abaloparatide has greater selec-
tivity for the RG conformation than teriparatide and is thought
to promote more transient signalling which results in an ana-
bolic effect with less resorption [2].
Bone turnover markers (BTMs) can be used to monitor the
effects of osteoporosis treatment. The International
Osteoporosis Foundation has proposed that the reference mark-
er for bone formation should be procollagen type I N propeptide
(s-PINP) and serum carboxy-terminal cross-linking telopeptide
of type I collagen (s-CTX) for bone resorption [3].
s-PINP has proven to be the most sensitive marker for
detecting the response of bone turnover to teriparatide [4]. S-
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PINP increases within 3 days of starting this treatment [5] and
reaches a peak after 3 to 6 months of treatment [6]. The early
change in s-PINP correlates with the later change in BMD
whether the treatment was with teriparatide [7, 8] or PTH 1-
84 [9]. The relationship between early changes in biochemical
markers of bone turnover and subsequent BMD response to
abaloparatide has not been examined.
The ACTIVE Study compared abaloparatide with blinded
placebo and with open-label teriparatide over 18 months [10].
In ACTIVE, the increase in lumbar spine BMD was similar
for abaloparatide compared to teriparatide and the increase in
total hip BMD was greater for abaloparatide, yet the increase
in the bone formation marker s-PINP was lower with
abaloparatide than teriparatide. The increase in the bone re-
sorption marker s-CTX was also lower, raising the question of
whether the relative increase of formation and resorption
might differ and explain the differences in the pattern of
BMD changes. The relative changes in bone resorption and
formation can be estimated mathematically by calculating the
mean and standard deviation of the relevant markers and
subtracting resorption from formation [11]. This approach
has been used during therapy of glucocorticoid-induced oste-
oporosis with teriparatide [12].
If the PINP is increased more by teriparatide than by
abaloparatide, then why is the increase in BMD at the spine
at 18 months similar for the two drugs and the increase in
BMD at the total hip at 18 months different? Perhaps this
could be explained by studying the relationship between the
change in bone formation and bone resorption markers quan-
titatively using an ‘uncoupling index’.
Materials and methods
Subjects
The Abaloparatide Comparator Trial In Vertebral Endpoints
(ACTIVE) was a phase 3, double-blind, randomised con-
trolled trial conducted at 28 sites in 10 countries [10].
Postmenopausal women with bone mineral density (BMD)
T-score ≤ − 2.5 and > − 5.0 at the lumbar spine or femoral
neck and radiological evidence 2 mild or 1 moderate lumbar
or thoracic vertebral fracture or history of low-trauma
nonvertebral fracture within the past 5 years were eligible.
Postmenopausal women (> 65 years) meeting the fracture
criteria and having a T-score between − 2.0 and > − 5.0, or
not meeting the fracture criteria and having a T-score between
− 3.0 and > − 5.0, could enrol. The abaloparatide 80 μg group
(n = 824) and placebo group (n = 821) received masked pens
that were identical in appearance, while the teriparatide 20 μg
group (n = 818) was open-label and patients received com-
mercial teriparatide pens.
Sample collection and BTM analyses
In the phase 3 ACTIVE, blood samples were taken under
fasting conditions at baseline and 1, 3, 6, 12, and 18 months
and measured for BTMs among a subset of patients who were
randomly selected from all sites based on a simple random
selection procedure in a treatment-blinded fashion to reach a
target sample size of 600 (approximately 200 patients per
treatment group). Patients who did not complete the
ACTIVE trial were excluded from the random selection.
Validated bioanalytical assays for BTMs used the automat-
ed Roche Elecsys platform. Biomarker measurements were
performed at the Nordic Synarc Research Labs (Denmark)
using a COBAS E411 automated analyser (Roche
Diagnostics, Germany) according to the manufacturer’s in-
structions. The s-PINP intra-assay and inter-assay precision
was reported as < 2.9% and < 3.7%, respectively, with a lower
limit of quantification (LLOQ) and upper limit of quantifica-
tion (ULOQ) of 5 ng/ml and 1200 ng/ml, respectively. The s-
CTX intra-assay and inter-assay precision were reported as <
3.2% and < 3.4%, respectively, with an LLOQ and ULOQ of
0.010 and 6.0 ng/ml, respectively. We measured 1,25(OH)2D
by EIA (Immunodiagnostic Systems, Boldon, UK).
Statistical analysis
The correlation of change from baseline in concentration of s-
PINP and s-CTX at 1, 3, 6, 12, and 18 months was compared
with percent change from baseline in lumbar spine BMD at
18 months using Spearman’s rank correlation. Because the dis-
tribution of BTM data was skewed, we also evaluated the cor-
relation of the log ratio of s-PINP and s-CTX over baseline with
percent change from baseline in lumbar spine BMD at
18 months using Pearson’s correlation coefficients. For exam-
ple, if the PINP was 60 at follow-up and 50 at baseline, then we
would take the ratio, 1.2, and then its natural logarithm, 0.182.
Scatter plots between log ratio of s-PINP at 3 months and lum-
bar spine BMD percent change at 18 months were presented
with linear regression lines for abaloparatide and teriparatide.
To compare between treatments, Pearson correlation coeffi-
cients were assessed using the Z-score test after Fischer’s Z
transformation. T test was used to assess the difference in slopes
of the regression lines between the two treatment groups.
The ‘uncoupling index’ (UI) was calculated as the Z-score
of log s-PINP minus the Z-score of log s-CTX. The Z-score
standardised marker values were calculated by taking the dif-
ference between each subject’s bone turnover marker and the
mean of all subjects’ bone turnover markers at baseline divid-
ed by the associated standard deviation.
All tests were 2-sided and performed at a significance level
of 0.05, with no adjustment for multiple comparisons.
Analyses used observed data without imputing for missing
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values. The statistical software used was SAS version 9.4
(SAS Institute, Cary, NC).
Results
Among the 600 randomly selected patients in the BTM subset,
184 received placebo, 189 received abaloparatide, and 227
received teriparatide. The baseline demographics were similar
between the abaloparatide and the teriparatide groups
(Table 1). They were also similar to the patients treated in
the main trial with abaloparatide (n = 824) and teriparatide
(n = 818) [10].
The serum concentrations of s-PINP and s-CTX during
treatment and the uncoupling index (UI) are shown in
Fig. 1. Both abaloparatide and teriparatide increased s-
PINP and s-CTX concentrations as reported by Miller
[10]. The pattern of increase was similar for the two
agents during the first 3 months of treatment, but thereaf-
ter, s-PINP and s-CTX concentrations were greater for
teriparatide than abaloparatide. Despite these differences,
the UI was generally similar for abaloparatide and
teriparatide during 18 months of treatment. The mean UI
was moderately greater for abaloparatide than teriparatide
at 1 month (1.743 vs 1.493, respectively; P = 0.03), but
not at 3 months (Fig. 1, Table 2) or at later time points.
For patients included in this BTM analysis, BMD increased
at the lumbar spine, total hip, and femoral neck with
abaloparatide and teriparatide similar to the overall cohort
[10]. After 18 months of treatment, the percentage change in
lumbar spine BMD was similar between agents, but the per-
centage increase in total hip and femoral neck BMD was
Table 1 Baseline demographics and characteristics
Abaloparatide Teriparatide
Variable (N = 189) (N = 227)
Age (years), Mean (SD) 68.6 (6.5) 68.4 (6.6)
Race n (%)
White 154 (81.5) 182 (80.2)
Asian 28 (14.8) 35 (15.4)
Black or African American 6 (3.2) 6 (2.6)
Other 1 (0.5) 4 (1.8)
Hispanic or Latino 40 (21.2) 48 (21.1)
BMI (kg/m2), mean (SD) 25.0 (3.2) 25.4 (3.5)
Prevalent vertebral fracture, n (%) 45 (23.8) 59 (26.0)
No prior fracture, n (%) 66 (34.9) 88 (38.8)
Bone mineral density, T-score, mean (SD)
Lumbar spine − 2.9 (0.88) − 2.8 (0.85)
Femoral neck − 2.1 (0.63) − 2.1 (0.65)
Total hip − 1.8 (0.77) − 1.8 (0.75)
Bone turnover markers, mean (SD)
s-PINP (ng/mL) 54.5 (20.7) 53.5 (20.6)
s-CTX (ng/mL) 0.49 (0.19) 0.48 (0.20)
BMI, body mass index; BTM, bone turnover markers; s-CTX, serum
carboxy-terminal cross-linking telopeptide of type I collagen; SD, stan-
dard deviation; s-PINP, procollagen type I N propeptide
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Fig. 1 Median (interquartile range) of s-PINP, s-CTX andmean (95%CI)
of uncoupling index over time during treatment with placebo,
abaloparatide, or teriparatide over 18 months
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significantly greater for abaloparatide as compared to
teriparatide (Fig. 2).
There was a significant correlation between early
change in s-PINP and subsequent increases in BMD for
both therapies. The strongest correlations between s-PINP
and BMD were observed between 3 and 6 months; the 3-
month time point was considered most clinically useful
for providing early feedback and is described in more
detail. The relationship between the log ratio of s-PINP
at 3 months and percentage change in lumbar spine at
18 months for abaloparatide was r = 0.561 (P < 0.0001)
and r = 0.198 (P = 0.003) for teriparatide; the correlation
coefficient for abaloparatide was significantly larger than
for teriparatide (P < 0.0001) (Table 3, Fig. 3). The removal
of an outlying point (ratio of about 20) only had a small
effect on this correlation for the teriparatide group (it
changed from an r value of 0.198 to 0.215). The slope
of the regression line between log ratio of s-PINP at
3 months and increase in lumbar spine BMD at 18 months
was greater for abaloparatide (slope = 5.96) than for
teriparatide (slope = 2.39) (Fig. 3; P = 0.0005) indicating
that a similar early increase in s-PINP was associated with
a greater increase in subsequent lumbar spine BMD. A
significant correlation between the 3-month log ratio of
s-PINP and total hip BMD was also observed for
abaloparatide (r = 0.273; P < 0.001) but not for teripa-
ratide (Table 3).
There was also a significant correlation between early
change in s-CTX and subsequent increases in BMD. The re-
lationship between change in the log ratio of s-CTX at
3 months and percentage change in lumbar spine BMD at
18 months for abaloparatide was r = 0.451 (P < 0.0001) and
r = 0.042 (P = 0.53) for teriparatide; the correlation coefficient
for abaloparatide was significantly larger than for teriparatide
(P < 0.0001) (Table 3, Fig. 3). A significant correlation be-
tween the 3-month log ratio of s-CTX and total hip BMD
was also observed for abaloparatide (r = 0.166; P = 0.023),
but not for teriparatide (Table 3).
We also examined the relationship between the UI and
subsequent increases in BMD. There was a significant
correlation between the 3-month UI for abaloparatide
and lumbar spine BMD after 18 months (r = 0.247;
P < 0.001), but not for teriparatide (r = 0.115; P = NS;
P = NS for the comparison between UI for abaloparatide
versus teriparatide) (Table 3). A similar pattern was ob-
served with total hip BMD (Table 3).
The changes in BTM could be influenced by changes in
1,25(OH)2D. However, the mean increases in 1,25(OH)2D at
1, 6, and 18 months for treatment with abaloparatide were 26,
16, and 13% and for teriparatide were 27, 18, and 15%.
Fig. 2 Mean change (95% CI) in
lumbar spine and total hip BMD
over time during treatment with
placebo, abaloparatide, or
teriparatide over 18 months for
patients included in the BTM
analysis
Table 2 Summary of bone turnover markers and the uncoupling index
at 3 months
Abaloparatide Teriparatide
N = 189 N = 227 P value
s-PINP at baseline (ng/mL)
Median (IQR) 50.6 (40.8, 65.3) 49.9 (39.4, 63.8) 0.435
Δs-PINP at month 3 (ng/mL)
Median (IQR) 28.9 (3.2, 81.8)* 47.8 (20.9, 76.8) 0.005
Log ratio of s-PINP at month 3 over baseline
Mean (SD) 0.56 (0.66)* 0.68 (0.45) 0.016
s-CTX at baseline (ng/mL)
Median (IQR) 0.48 (0.34, 0.59) 0.45 (0.34, 0.58) 0.361
Δs-CTX at month 3 (ng/mL)
Median (IQR) 0.07 (−0.04, 0.33)* 0.20 (0.07, 0.39) < 0.0001
Log ratio of s-CTX at month 3 over baseline
Mean (SD) 0.23 (0.54)* 0.41 (0.40) < 0.0001
UI (Zlog(s-PINP) – Zlog(s-CTX)) at month 3
0.88 (1.05)* 0.259
Mean (SD) 0.76 (0.96)
*N = 187
IQR, interquartile range; s-CTX, serum carboxy-terminal cross-linking
telopeptide of type I collagen; SD, standard deviation; s-PINP,
procollagen type I N propeptide
Osteoporos Int
Discussion
In this study, we have tried to explain why two anabolic drugs
differ in the increase in the bone formation marker s-PINP, yet
had similar lumbar spine BMD increase. We think this might
be explained by an alteration in the relationship between
change in s-PINP and BMD and by the similarity in the in-
crease in s-PINP relative to s-CTX.
We concluded this because we had examined the relation-
ship between changes in BTMs and changes in BMD and
found that this relationship differed for abaloparatide and
teriparatide, with the slope being steeper for abaloparatide. It
is unknown as to why the relationship is different for these two
drugs. It may be that the relative effects on modelling and
remodelling differ, but this would require a comparative study
of bone histomorphometry.
An alternative, yet speculative, explanation is that regions
of the skeleton differ in their responses to the treatments.
BTMs reflect metabolism occurring within the entire skeleton;
hence, if there were particularly potent effects of teriparatide
on the skull [13], this would result in greater increases in
BTMs, but not greater anabolic effects on BMD at the lumbar
spine or total hip.
We hypothesised that the change in balance between for-
mation and resorption early in treatment would be more
predictive of 18-month change in lumbar spine BMD than
a single marker of either formation or resorption alone.
Thus, we calculated the UI, which increased in response to
both anabolic agents. Such a finding has been reported pre-
viously for teriparatide in glucocorticoid-induced osteoporo-
sis, with a value of about 2 at 3 months [12]. However, the
UI was calculated differently in the current study as we
addressed the skewed distribution of the BTMs by logarith-
mic transformation. We had used a similar approach recently
to demonstrate an increase in bone turnover associated with
bone loss in postmenopausal women [14]. The early differ-
ence in UI between treatments at 1 month, which was no
longer apparent at 3 months or later time points, could help
explain why lumbar spine BMD increased more quickly
with abaloparatide but was similar to teriparatide after
18 months; however, this does not fully explain why there
was a greater increase in proximal femur BMD with
abaloparatide.
Bone histology has been reported for the ACTIVE study
[15]. It would be helpful in the future to reconstruct the bone
remodelling cycle in order to calculate ‘bone balance from
resorption depth and mean wall thickness’ as this is the histo-
logical equivalent of ‘uncoupling index’.
The strengths of our study are the large sample size given
that we are studying surrogates, the continuous outcomes,
and the inclusion of both teriparatide and abaloparatide in
the same study, with patients randomly assigned to treat-
ment. Also, the BTM and BMD were measured using
state-of-the-art techniques, and we analysed the data while
taking account of the skewed distribution of BTMs. The
weaknesses are that teriparatide was given as an open-label
treatment and there is an insufficient number of fractures to
compare the relationship between changes in bone turnover
markers and fracture.
Table 3 Correlation of bone turnover marker at 3 months and percent
change in bone mineral density at 18 months
Lumbar spine BMD Total hip BMD
ABL TPTD ABL TPTD
Baseline s-PINP
n 188 227 189 225
Corr. Coef. 0.088 0.274 0.155 0.249
P value 0.229 < 0.0001 0.034 < 0.001
Δs-PINP at 3 months
n 186 227 187 225
Corr. Coef. 0.536 0.264 0.280 0.043
P value < 0.0001 < 0.001 < 0.001 0.519
Log ratio of s-PINP at 3 months over baseline
n 186 227 187 225
Corr. Coef. 0.561 0.198 0.273 − 0.054
P value < 0.0001 0.003 < 0.001 0.422
P value of ABL Corr Coef vs TPTD Corr Coef
< 0.0001 < 0.001
Baseline s-CTX
n 188 227 189 225
Corr Coef 0.175 0.309 0.128 0.237
P value 0.016 < 0.0001 0.079 < 0.001
Δs-CTX at 3 months
n 186 227 187 225
Corr Coef 0.439 0.156 0.139 0.031
P value < 0.0001 0.019 0.058 0.640
Log ratio of s-CTX at 3 months over baseline
n 186 227 187 225
Corr Coef 0.451 0.042 0.166 − 0.111
P value <0.0001 0.530 0.023 0.096
P value of ABL Corr Coef vs TPTD Corr Coef
< 0.0001 0.005
UI (Zlog(s-PINP) – Zlog(s-CTX)) at month 3
n 186 227 187 225
Corr Coef 0.247 0.115 0.257 0.032
P value < 0.001 0.083 < 0.001 0.635
P value of ABL Corr Coef vs TPTD Corr Coef
0.171 0.021
ABL, abaloparatide; BMD, bone mineral density; Corr Coef, correlation
coefficient; s-CTX, serum carboxy-terminal cross-linking telopeptide of
type I collagen; s-PINP, procollagen type I N propeptide; TPTD,
teriparatide
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In conclusion, early changes in s-PINP correlate with the
percentage change in lumbar spine BMD after 18 months of
treatment with both abaloparatide and teriparatide, although
the correlation with abaloparatide was greater. The UI was
generally similar between abaloparatide and teriparatide,
supporting that while absolute levels of s-PINP and s-CTX
were lower with abaloparatide than teriparatide, the balance
between the formation and resorption marker was similar.
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